echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The first long-acting HIV preventive treatment that has been given priority review by the FDA is coming?

    The first long-acting HIV preventive treatment that has been given priority review by the FDA is coming?

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 28, 2021, ViiV Healthcare announced that the US FDA has granted Cabotegravir's New Drug Application (NDA) priority review as a long-acting injection therapy for HIV pre-exposure prevention (PrEP)


    Cabotvir is an innovative antiviral drug developed by ViiV Healthcare


    The new drug application is based on the results of two phase 2b/3 clinical trials


    ▲The molecular structure of Cabotvir (picture source: PubChem)

    In terms of safety, the most common adverse reactions (all grades) observed were injection site reactions, diarrhea, headache, fever, fatigue, sleep disturbance, nausea, dizziness, flatulence and abdominal pain


    Reference materials:

    [1] FDA grants Priority Review to ViiV Healthcare's New Drug Application for cabotegravir long-acting for prevention of HIV.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.